Conferenza stampa Farma Industria Ticino – 30 maggio 2022

3 June 2022

Healiva® acquisisce da Smith+Nephew due asset di terapia cellulare per la guarigione delle ferite

2 June 2022

Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy

30 May 2022

Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer

20 May 2022

Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference

17 May 2022

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

17 May 2022

United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association

12 May 2022

Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*

6 May 2022

Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)

27 April 2022

FIT premia il miglior lavoro di diploma nella Tecnica dei sistemi chimico-farmaceutica della SSST

29 March 2022